Israel’s Nasus Pharma (see here previously) has reported positive results from its latest clinical study of its FMXIN002 intranasal Epinephrine powder spray device. It provides a safe and effective rescue for the emergency treatment of life-threatening allergic reactions. https://www.prnewswire.com/news-releases/nasus-pharma-announces-publication-of-its-positive-clinical-results-with-fmxin002-intranasal-powder-epinephrine-spray-in-the-journal-of-allergy-and-clinical-immunology-in-practice-301895372.html https://pubmed.ncbi.nlm.nih.gov/37394178/

In recent trials at Israel’s Sheba Medical Center, the Taffix nose spray from Israel’s Nasus (see here previously) blocked 100 percent” of the British and South African variants of SARS-CoV-2 virus. https://nocamels.com/2021/04/israeli-nasus-nasal-spray-taffix-covid-variants/ https://www.youtube.com/watch?v=MqdurzubL18

Israeli biotech Nasus has developed the Taffix anti-viral nasal spray. It creates a thin gel over the nasal mucosa, blocking viruses for 4-5 hours. In recent tests, Taffix reduced Covid-19 infections from 10% down to 2.4%. Taffix is marketed in … Continue reading →